Antinociceptive effect induced by the combined administration of spinal morphine and systemic buprenorphine

Anesthesia and Analgesia

Volumn 87, Issue 3, 1998, Pages 583-586

  Niv, David ^a   Nemirovsky, Alexander ^b,d   Metzner, Julia ^a   Rudick, Valery ^a   Jurna, Ilmar ^c   Urca, Gideon ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c SAARLAND UNIVERSITY   (Germany)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; MORPHINE; NARCOTIC ANALGESIC AGENT;

ANALGESIA; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; DOSE RESPONSE; DRUG EFFECT; INTRAPERITONEAL DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; MALE; NOCICEPTION; NONHUMAN; PAIN; PRIORITY JOURNAL; RAT;

EID: 0031656205     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/00000539-199809000-00016     Document Type: Article

References (25)

1. Yeung JC, Rudy TA. Multiplicative interaction between narcotic agonisms expressed at spinal and supraspinal sites of antinociceptive action as revealed by concurrent intrathecal and intracerebroventricular injections of morphine. J Pharmacol Exp Ther 1980;215:633-42.
2. Roerig SC, Fujimoto JM. Multiplicative interaction between intrathecally and intracerebroventricularly administered mu opioid agonists but limited interactions between delta and kappa agonists for antinociception in mice. J Pharmacol Exp Ther 1989;249:762-8.
3. Niv D, Nemirovsky A, Rudick V, et al. Antinociception induced by simultaneous intrathecal and intraperitoneal administration of low doses of morphine. Anesth Analg 1995;80:886-9.
4. Pasternak GW. Pharmacological mechanisms of opioid analgesics. Clin Neuropharmacol 1993;16:1-19.
5. Hoskin PJ, Hanks GW. Opioid agonist-antagonist drugs in acute and chronic pain states. Drugs 1991;41:326-44.
6. Downing JW, Leary WP, White ES. Buprenorphine: a new potent long acting synthetic analgesic - comparison with morphine. Br J Anaesth 1977;49:251-4.
7. Heel RC, Brogden RN, Speight TM, Avery GS. Buprenorphine: a review of its pharmacological properties and therapeutic efficacy. Drugs 1979;17:81-110.
8. MacLean D, MacConnachie AM. Clinical uses of the new synthetic opioids. Hospital Update 1987;13:1046-55.
9. Bullingham RES, McQuay H, Dwyer D, et al. Sublingual buprenorphine used post-operatively: clinical observations and preliminary pharmacokinetic analysis. Br J Clin Pharmacol 1981; 12:117-22.
10. Martin H, Kocher L, Chery-Croze S. Chronic lumbar intrathecal catheterization in the rat with reduced length spinal compression. Physiol Behav 1984;33:159-61.
11. Ben-Bassat J, Petretz E, Sulman FG. Analgesimetry and ranking of analgesic drugs by the receptacle method. Arch Int Pharmacodyn Ther 1959;122:434-47.
12. Tallarida RJ, Murray RB. Manual of pharmacologic calculations with computer programs. 2nd ed. New York: Springer-Verlag, 1986.
13. Berenbaum MC. What is synergy? Pharmacol Rev 1989;41: 93-141.
14. Cousins MJ, Mather LE. Intrathecal and epidural administration of opioids. Anesthesiology 1984;61:276-310.
15. Bromage PR. Dangers and complications of intrathecal and epidural opiates. In: Yaksh TL, Muller H, eds. Spinal Opiate analgesia: experimental and clinical studies. Berlin: Springer-Verlag, 1982:18-23.
16. Bromage PR, Camporesi EM, Durant PAC, Nielsen CH. Rostral spread of epidural morphine. Anesthesiology 1982;56:431-6.
17. Richards ML, Sadee W. Buprenorphine is an antagonist at the kappa opioid receptor. Pharmacol Res 1985;178-81.
18. Leander JD. Buprenorphine has potent kappa opioid receptor antagonist activity. Neuropharmacology 1987;26:1445-7.
19. Gremek DE, Dykstra LA, Wood JH. Kappa opioids in rhesus monkeys: III - dependence associated with chronic administration. J Pharmacol Exp Ther 1987;242:428-36.
20. Nehus SS, Dykstra LA. Kappa antagonist properties of buprenorphine in the shock titration procedure. Eur J Pharmacol 1988;156:77-86.
21. Nehus SS, Picker MJ, Dykstra LA. Kappa antagonist properties of buprenorphine in non-tolerant rats. Psychopharmacology 1989;98:141-3.
22. Wood PL. Opioid receptor affinities of kappa agonists, agonists/antagonists and antagonists in vitro and in vivo. Prog Neuropsychopharmacol Biol Psychiatry 1983;7:657-62.
23. Sheldon RJ, Nunan L, Porreca F. U50,488H differentially antagonizes the bladder effects of mu agonists at spinal sites. Eur J Pharmacol 1988;146:229-35.
24. Sheldon RJ, Nunan L, Porreca F. Differential modulation by [D-Phen2, D-Phen5] enkephalin and dynorphin A-(1-17) of the inhibitory bladder motility effects of selected mu-agonists in vivo. J Pharmacol Exp Ther 1989;249:462-9.
25. Qi JA, Heyman JS, Sheldon RJ, et al. Mu antagonist and kappa agonist properties of beta-funaltrexamine (beta-FNA) in vivo: long-lasting spinal analgesia in mice. J Pharmacol Exp Ther 1990;252:1006-11.